Prime management will participate in a fireside chat at an H.C. Wainwright conference this month. Details: investors.primemedicine.com/news-releases/… $PRME

#TIDES2024 kicks off tomorrow here in Boston, and we look forward to presentations from several Prime team members throughout the week! Join us live at TIDES and learn more below.

We are thrilled to congratulate David R. Liu, 2024 recipient of the ASGCT Outstanding Achievement Award, in recognition of his significant contributions to the field of gene and cell therapy. Congratulations, David, on this well-deserved honor!

We are pleased to report new preclinical data demonstrating the ability of PM359 to correct a common disease-causing mutation of CGD. Dr. Jennifer Gori will present these findings at #ASGCT2024 this evening. Full details: investors.primemedicine.com/news-releases/…

Prime team members are in Baltimore to present data at #ASGCT2024 . We invite you to join us live or to listen in virtually to these presentations. Thank you to the ASGCT team for their work curating another valuable event!

#ICYMI : We received IND clearance for PM359 for the treatment of CGD, enabling us to initiate our Phase 1/2 clinical trial in the US. We are thrilled to bring our first Prime Editor product candidate into the clinic. CEO Keith Gottesdiener reflects on this milestone below.

CEO Keith Gottesdiener will be speaking at #MIGlobal 's Things That Will Blow Your Mind session next week in Los Angeles. Check out the agenda for this year's Milken Institute Global Conference below.
milkeninstitute.org/events/global-…

Team members Marine Hatit and Douglas Scott will present at the LNP Formulation & Process Summit in Boston this week. View the full agenda: …lation-process-development-pharma.com

We are pleased to announce that #FDA has cleared our IND application for PM359 for the treatment of chronic granulomatous disease (CGD), enabling Prime to initiate its Phase 1/2 clinical trial in the US. Details: investors.primemedicine.com/news-releases/… $PRME

Spring has sprung, and our next class of co-op students have arrived! Our 21 spring co-ops are settled in across all departments, from the lab to finance. We look forward to having them on our team the next few months.

We are pleased to share members of our team will be sharing preclinical data updates across our pipeline at various upcoming conferences. Details: investors.primemedicine.com/news-releases/…

March is #WilsonsDisease Awareness Month. This condition affects 1 in every ~30,000 people. There is currently no cure, and lifelong treatment is necessary. We're proud to be part of efforts dedicated to seeking better treatment options.

Head of Process Chemistry Rowshon Alam will be presenting Prime research at #TIDESAsia this week. More details here. informaconnect.com/asia-tides/spe…

Prime CTO Ann Lee will be speaking at the Gordon Research Conferences on Biotherapeutics and Vaccines Development next week. Learn more below and find the agenda here. grc.org/biotherapeutic…

Of the 7,000+ rare diseases that have been identified, approximately 72% are genetic, and there's a real need for more long-lasting, effective treatments for these conditions. In honor of #RareDiseaseDay , we showed our support for those living with rare diseases. #ShowYourStripes

Members of leadership will participate in investor events with #Cowen and #Jefferies next month. Full details: investors.primemedicine.com/news-releases/… $PRME

Tune into the latest episode of Alix Ventures' BIOS Builders podcast to hear CEO Keith Gottesdiener's insights into the current gene editing landscape, Prime's path forward in 2024 and more. ⬇️

CEO Keith Gottesdiener and @BradLoncar discuss Prime's science and vision for the future on the latest episode of BiotechTV. Listen in.

Prime management will participate in #Guggenheim Healthcare Talks this month. Details here. investors.primemedicine.com/news-releases/… $PRME

Orphan Drug Designation has been granted to a Prime Edited CD34+ cell-based drug product for the treatment of #CGD . This is an exciting step forward as we work to transform the lives of patients through the application of our groundbreaking Prime Editing platform and technology.